The latest results of oral antiviral therapy that are effective and have preventive potential for all new crown variants are released

A few days ago, Atea Pharmaceuticals announced the latest clinical trial results of the oral antiviral therapy AT-527 jointly developed by the company and Roche in its financial report for the second quarter of 2021

Recently, multiple variants of the new coronavirus have been widely circulating around the world, and they more or less have a certain immune evasion ability, which may reduce the protective efficacy of existing vaccines

▲The epidemic of new crown variants requires a variety of treatment and prevention strategies (picture source: reference [2])

The results of the ongoing global phase 2 clinical trial show that among hospitalized COVID-19 patients with a high viral load at baseline, the use of AT-527 reduces the virus levels in the patients more rapidly than placebo and makes more Many patients reach a negative state of virus testing earlier

▲AT-527 (green) compared with placebo (red), allows patients to reach the virus test negative standard earlier (picture source: reference [2])

Studies conducted in healthy volunteers have shown that the level of the active metabolite of AT-527 in the lung lining fluid reaches the target antiviral level (see figure below)

Picture source: reference [2]

In addition, preclinical studies have shown that AT-527 will not introduce mutations into the viral genome

Currently, Atea and Roche are conducting a number of clinical trials to test the efficacy of AT-527 in hospitalized and non-hospitalized COVID-19 patients.

Reference materials:

[1] Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results.

[2] Second Quarter 2021 Financial Results, Clinical and Corporate Update.